Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey

Oncology

Volumn 70, Issue 1, 2006, Pages 34-48

  Barrett Lee, Peter J ^a   Ludwig, Heinz ^b   Birgegård, Gunnar ^c   Bokemeyer, Carsten ^d   Gascón, Pere ^e   Kosmidis, Paris A ^f   Krzakowski, Maciej ^g   Nortier, Johan W R ^h   Kongable, Gail ⁱ   Schneider, Maurice ^j   Schrijvers, Dirk ^k   Van Belle, Simon J ^l  

^a Velindre NHS Trust   (United Kingdom)

^b WILHELMINEN HOSPITAL   (Austria)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e HOSPITAL CLÍNIC   (Spain)

^f HYGEIA HOSPITAL   (Greece)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Epsilon Group   (United States)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k ZNA Middelheim   (Belgium)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Anemia; Cancer; Chemotherapy; Logistic regression analysis; Risk model

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLATINUM;

ADULT; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GYNECOLOGIC CANCER; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPLIT HALF CORRELATION;

ADULT; AGED; ANEMIA, HYPOCHROMIC; AREA UNDER CURVE; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK FACTORS; ROC CURVE;

EID: 33644910923     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091675     Document Type: Review

References (31)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
3. Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 2001;28(suppl 8):7-14.
4. Mercadante S, Gebbia V, Marrazzo A, Filosto S: Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
5. Jacobsen PB, Thors CL, Cawley M, Ax E, Grendys EC: Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment (abstract). Proc Am Soc Clin Oncol 2002;21:386.
6. O'Shaughnessy J: Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs 2003;19(4 suppl 2):17-24.
7. Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(suppl 2):S2-S8.
8. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535-2542.
9. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E: Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-2329.
10. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
11. Demetri GD, Kris M, Wade J, Degos L, Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
12. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
13. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
14. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221.
15. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
16. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
17. Cancer Therapy Evaluation Program: Common Toxicity Criteria, v2.0. Bethesda, National Cancer Institute, 1998.
18. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001;37:1617-1623.
19. Zou KH, Warfield SK, Fielding JR, Tempany CMC, Wells WM 3rd, Kaus MR, Jolesz FA, Kikinis R: Statistical validation based on parametric receiver operating characteristic analysis of continuous classification data. Acad Radiol 2003;10:1359-1368.
20. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY: Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999;17:2840-2846.
21. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, Schneider M, Magne N, Bensadoun RJ, Renee N, Milano G: An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000;36:852-857.
22. Strauss DJ: Epoetin alfa therapy for patients with hematologic malignancies and mild anemia. Clin Lymphoma 2003;4(suppl 1):13-17.
23. Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
24. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
25. Food and Drug Administration/Oncologic Drugs Advisory Committee: May 4, 2004 Briefing Information. http://www.fda.gov/ ohrms/dockets/ac/04/briefing/ 4037b2.htm.
26. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 suppl 2):13-19.
27. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(3 suppl 2):4-12.
28. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
29. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971-975.
30. Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, Hejna M, Zochbauer S, Krajnik G, Huber H, Fleischhacker WW, Sperner-Unterweger B: The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-973.
31. O'Shaughnessy J, Vukelja SJ, Savin M, Holmes FA, Jones M, Royall D, George MJ, Von Hoff DD: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data (abstract). Breast Cancer Res Treat 2002;76:S138.